Patients with psoriatic arthritis (PsA) have a higher prevalence of diabetes mellitus (DM) compared to the general population ...

Objective To summarise the evidence on effectiveness of non-pharmacological (ie, non-drug, non-surgical) interventions on work participation (sick leave, work status and presenteeism) in people with ...

Objective To determine the contribution of clinical and biochemical inflammation to structural progression of patients with psoriatic arthritis (PsA).Methods We analysed patients from the Infliximab ...

Objective To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment.Methods Participants with PsA were treated with guselkumab or ...

Objective Rheumatoid arthritis (RA) and Sjögren’s disease (SjD) are two rheumatic autoimmune diseases that commonly co-occur. Besides some overlap in clinical presentation, the two diseases share the ...

Background Different patient clusters were preliminarily suggested to dissect the clinical heterogeneity in Still’s disease. Thus, we aimed at deriving and validating disease clusters in a multicentre ...

Systemic lupus erythematosus (SLE) is a heterogenic connective tissue disease with a broad spectrum of clinical and laboratory manifestations. Due to this heterogeneity, SLE remains challenging to ...

Results The OR (95% CI) for ASAS20 response for the presence of nail dystrophy was 3.2 (95% CI 0.93 to 10.99) in the secukinumab 150 mg group and 5.0 (95% CI 1.47 to 17.19) in the secukinumab 300 mg ...

Peripheral spondyloarthritis (pSpA) refers to a number of seemingly different spondyloarthritis subsets in which psoriatic arthritis (PsA) is the most common, and symptoms of arthritis, enthesitis or ...

Despite the high mortality risk, no specific treatment options for cardiac manifestations in systemic sclerosis (SSc) currently exist. We performed a retrospective medical records analysis at our ...

Objective To evaluate the reliability of concurrent flare identification using 3 methods (patient, rheumatologist and Disease Activity Score (DAS)28 criteria), and construct validity of candidate ...

Objective To investigate the efficacy, safety, immunogenicity and pharmacokinetics of biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced reference ADL (ADL-EU) in ...